Highlights from China's Pharma & Healthcare Industry

2019 saw the 10-year anniversary of China's medical reform under which the country's health sector has seen a new era of progress.

webversion  Highlights from China's Pharma & Healthcare Industry After 10-year medical reform in China,  the country's health sector has seen a new era of progress, highlighted by restructured government framework and tangible outcomes such as universal health coverage, hospital reform and medical insurance payment to the drug supply system. Under the Belt and Road Initiative, overseas investment grew rapidly along with M&A and in and out-licensing, whilst the healthcare reform continued to unleash new market opportunities.  The accelerated clinical trial authorization, expedited review and approval procedures, expanded volume-based procurement, and innovative breakthrough designation, etc. are all encouraged due to regulatory reforms in China.  Want to Learn More?  If you'd like to learn more about China's healthcare industry, join us at CPhI & P-MEC China 2020 this December in Shanghai. There you'll have the chance to meet Chinese pharma experts and industry insiders who can share their first-hand knowledge, while learning from a comprehensive educational programme.  Get Your Free Event Pass CPhI & P-MEC China 2020, with the co-located shows FDF, bioLIVE, NEX, InnoPack and LABWORLD China, are expected to cover a total area of 210,000+ sqm, and draw 75,000+ visits of  professionals from the global pharmaceutical industry. Pre-register now for free to join us and celebrate the 20th anniversary of CPhI China at SNIEC, Shanghai during 16-18 December 2020!  Register Now for Free to Save CNY100 CPhI & P-MEC China 2020 16-18 December 2020 | SNIEC, Shanghai, China unsubscribe